39
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

      Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

      Aged, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carboplatin, Carcinoma, Non-Small-Cell Lung, drug therapy, genetics, pathology, Deoxycytidine, analogs & derivatives, Epithelial-Mesenchymal Transition, drug effects, Female, Gene Amplification, Humans, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases, antagonists & inhibitors, Receptors, Growth Factor, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

          Related collections

          Author and article information

          Journal
          21623265
          10.1097/JTO.0b013e31821528d3

          Comments

          Comment on this article